Your browser doesn't support javascript.
loading
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.
Holmström, Morten Orebo; Cordua, Sabrina; Skov, Vibe; Kjær, Lasse; Pallisgaard, Niels; Ellervik, Christina; Hasselbalch, Hans Carl; Andersen, Mads Hald.
Afiliação
  • Holmström MO; National Center for Cancer Immune Therapy, Herlev Hospital, Borgmester Ib Juuls Vej 25C, 5. Sal, 2730, Herlev, Denmark. holmeren1@yahoo.dk.
  • Cordua S; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Kjær L; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Pallisgaard N; Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.
  • Ellervik C; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hasselbalch HC; Department of Production, Research, and Innovation, Region Zealand, Sorø, Denmark.
  • Andersen MH; Department of Laboratory Medicine, Harvard Medical School, Boston Children's Hospital, Boston, USA.
Cancer Immunol Immunother ; 69(2): 315-324, 2020 Feb.
Article em En | MEDLINE | ID: mdl-31915854
There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (CALR) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR-mutation can recognize and kill autologous CALR-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR-mutant cells in the editing stage for several years. Thus, we suggest that CALR-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR-mutant MPN displays all three stages described in the theory of cancer immuno-editing.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Evasão Tumoral / Neoplasias Hematológicas / Suscetibilidade a Doenças / Imunomodulação Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Evasão Tumoral / Neoplasias Hematológicas / Suscetibilidade a Doenças / Imunomodulação Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article